<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457730</url>
  </required_header>
  <id_info>
    <org_study_id>1083575</org_study_id>
    <secondary_id>WIRB Protocol Number: 20061712</secondary_id>
    <nct_id>NCT00457730</nct_id>
  </id_info>
  <brief_title>A Study to Test the Use of Duloxetine for Pain in MS</brief_title>
  <official_title>A Randomized Placebo Controlled Trial of Duloxetine for Central Pain in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brown, Theodore R., M.D., MPH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown, Theodore R., M.D., MPH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients with Multiple Sclerosis experience pain that is caused by the effects of MS on
      the nervous system.

      The purpose of this study is to see if an investigational drug (Duloxetine) will reduce pain
      in subjects with MS.

      The US Food and Drug administration (FDA) has approved this drug for use with depression or
      pain from diabetes.However, it is considered investigational for this study because it has
      not been approved for patients with MS.

      This study will recruit patients with MS who have central pain which is 4 or greater on a
      scale of 1-10. Patients must have experienced pain for 2 months or longer prior to begining
      the study.The study will last 10 weeks, patients will be randomized either Duloxetine or
      placebo and will be carefully monitored throughout the study. Patients will keep pain/sleep
      diaries during the study period and will be provided Ibuprofen for pain control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Between 350,000 and 400,000 Americans have Multiple Sclerosis, a chronic neurological disease
      characterized by demyelination and axonal degeneration. Pain is an important symptom of MS,
      reported in 44% to 80% of patients.

      Duloxetine is FDA apprBetween 350,000 and 400,000 Americans have Multiple Sclerosis, a
      chronic neurological disease characterized by demyelination and axonal degeneration. Pain is
      an important symptom of MS, reported in 44% to 80% of patients.

      Duloxetine is FDA approved for use in treatment of diabetic painful neuropathy and
      depression. Since the analgesic mechanism of action of Duloxetine is believed to occur in the
      Central Nervous System, there is reason to believe that it may also be effective in central
      pain conditions, such as MS.

      Our study design includes a 1:1 randomization of Duloxetine to placebo. We hypothesize that
      the Duloxetine group will experience reductions in the weekly 24 hour average and worst pain
      scores that exceed 1.5 and that are significantly greater than reductions achieved in the
      placebo group. We also hypothesize that Duloxetine will be well tolerated with no significant
      group differences in adverse effects, sleep and quality of life as measured by the SF-36
      approved for use in treatment of diabetic painful neuropathy and depression. Since the
      analgesic mechanism of action of Duloxetine is believed to occur in the Central Nervous
      System, there is reason to believe that it may also be effective in central pain conditions,
      such as MS.

      Our study design includes a 1:1 randomization of Duloxetine to placebo. We hypothesize that
      the Duloxetine group will experience reductions in the weekly 24 hour average and worst pain
      scores that exceed 1.5 and that are significantly greater than reductions achieved in the
      placebo group. We also hypothesize that Duloxetine will be well tolerated with no significant
      group differences in adverse effects, sleep and quality of life as measured by the SF-36.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Worst Pain Score</measure>
    <time_frame>at week 6</time_frame>
    <description>Weekly mean of 24 hour Worst Pain Score, percent change from baseline. Range is 0-10 with 0= no pain and 10= worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Average Pain Score.</measure>
    <time_frame>at week 6</time_frame>
    <description>Percent change in Weekly mean of 24 hour Average pain Score, Week 6 vs. baseline. Range is 0-10 with 0= no pain and 10= worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression of Change</measure>
    <time_frame>Week 6 vs baseline</time_frame>
    <description>global impression: &quot;How do you feel about the effects of the medication over the past 7 days? 7 point scale, 7 = delighted, 1= terrible</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects are randomized to either Duloxetine or Placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MS made at least 3 months prior based on McDonald or Proser criteria.

          -  Age over 17.

          -  Clinical stability defined as no MS exacerbation or change in disease modifying
             therapy for 90 days prior to screening.

          -  Daily pain attributed to MS, present for a minimum of 2 months prior to screening.

          -  Minimum baseline score of 4 on the 24-h Worst Pain Score rated on an 11 point (0-10)
             point Likert Scale within the identified region of central pain.

        Exclusion Criteria:

          -  Pain that could not clearly be differentiated from causes other than Multiple
             Sclerosis, such as diabetic neuropathy, PVD, arthritis or other musculoskeletal
             condition, chronic headache, visceral pain.

          -  Transient pains such as dysesthetic L'Hermittes sign alone.

          -  Current or historical diagnosis of mania, bipolar disorder or psychosis.

          -  Concomitant use of monoamine oxidase inhibitors (MAOI) or thioridazine.(MAOI drug must
             be discontinued 14 days prior to enrollment. At least 5 days must have passed after
             study drug discontinuation before MAOI drug may be started.)

          -  Concomitant use of a serotonin reuptake inhibitor or venlafaxine or duloxetine within
             4 weeks of baseline.

          -  Use of any analgesic medication except ibuprofen for neurogenic pain 7 days prior to
             the baseline visit and until study termination.

          -  Use of an opioid, marijuana or dronabinol within 7 days of baseline.

          -  Narrow angle glaucoma.

          -  Depression with suicidality.

          -  Substantial alcohol use. Because it is possible that Duloxetine and alcohol interact
             to cause liver injury, duloxetine should not be prescribed to patients with
             substantial alcohol use. Potential subjects will be asked how much alcohol they drink.
             If the answer is over 2 drinks a day this will generally constitute an exclusion.

          -  History of chronic hepatic insufficiency or ALT or AST&gt; twice the upper limit of
             normal. Because it is possible thast Duloxetine may aggravate pre exisitng liver
             disease, duloxetine should not be prescribed to patients with chronic liver disease.

          -  Renal insufficiency (Creatinine Clearance , 30mL/minor serum creatinine &gt; 1.9).
             Duloxetine is not recommended for patients with end stage renal disease (requiring
             dialysis) or severe renal impairment. Population PK analyses suggest that mild to
             moderate degrees of renal dysfunction (estimated CrCl 30-80ml/min)have no significant
             effect on Duloxetine clearance. We will calculate creatinine clearance using the
             Cockcroft-Gault calculation. This is the most common calculation used in FDA producy
             labeling: Males=(140-age)(wt in kg)(serum creatinine)(72). Females= malesx 0.85.

          -  Uncontrolled hypertention (SBP&gt;180, DBP&gt;105)

          -  Females who are breast feeding, pregnant, or have potential to become pregnant during
             the course of the study.(fertile and unwilling/unable to use effective contraceptive
             measures)

          -  Any other serious and/or unstable medical condition.

          -  Allergy to ibuprofen or any other non steroidal anti inflammatory drug (NSAID)

          -  Any history of peptic ulcer disease within 2 years or lifetime history of
             NSAID-associated gastritis or other toxicity.

          -  Patients taking low dose aspirin will be instructed to contact their primary
             physicianto ask whether they may safely discontinue aspirin while participating in
             this study. If the recommendation is to continue aspirin or if use of aspirin is for
             secondary prevention of arteriosclerotic disease, then they will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore R Brown, MD.MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evergreen Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evergreen Healthcare</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <results_first_submitted>August 27, 2014</results_first_submitted>
  <results_first_submitted_qc>March 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2015</results_first_posted>
  <last_update_submitted>April 8, 2015</last_update_submitted>
  <last_update_submitted_qc>April 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown, Theodore R., M.D., MPH</investigator_affiliation>
    <investigator_full_name>Theodore R Brown</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Duloxetine</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine</title>
          <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
Placebo: Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
Placebo: Subjects are randomized to either Duloxetine or Placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine</title>
          <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
Placebo: Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
Placebo: Subjects are randomized to either Duloxetine or Placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
Placebo: Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
Placebo: Subjects are randomized to either Duloxetine or Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.71" spread="9.97"/>
                    <measurement group_id="B2" value="56.33" spread="11.23"/>
                    <measurement group_id="B3" value="56.3" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Worst Pain Score</title>
        <description>Weekly mean of 24 hour Worst Pain Score, percent change from baseline. Range is 0-10 with 0= no pain and 10= worst possible pain.</description>
        <time_frame>at week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
Placebo: Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
Placebo: Subjects are randomized to either Duloxetine or Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
Placebo: Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
Placebo: Subjects are randomized to either Duloxetine or Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Worst Pain Score</title>
          <description>Weekly mean of 24 hour Worst Pain Score, percent change from baseline. Range is 0-10 with 0= no pain and 10= worst possible pain.</description>
          <units>percent reduction on 0-10 analog scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.1" spread="20.4"/>
                    <measurement group_id="O2" value="-11.5" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Average Pain Score.</title>
        <description>Percent change in Weekly mean of 24 hour Average pain Score, Week 6 vs. baseline. Range is 0-10 with 0= no pain and 10= worst possible pain.</description>
        <time_frame>at week 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>ubjects will take 30 mg daily for 1 week, then 60 mg daily for 5 weeks, then titrate back down to 30 mg daily for 1 week.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo medication throughout 6 week observation period</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Average Pain Score.</title>
          <description>Percent change in Weekly mean of 24 hour Average pain Score, Week 6 vs. baseline. Range is 0-10 with 0= no pain and 10= worst possible pain.</description>
          <units>percent reduction on 0-10 analog scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.5" spread="29.1"/>
                    <measurement group_id="O2" value="-10.4" spread="18.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Impression of Change</title>
        <description>global impression: &quot;How do you feel about the effects of the medication over the past 7 days? 7 point scale, 7 = delighted, 1= terrible</description>
        <time_frame>Week 6 vs baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matched placebo medication with same periods</description>
          </group>
        </group_list>
        <measure>
          <title>Global Impression of Change</title>
          <description>global impression: &quot;How do you feel about the effects of the medication over the past 7 days? 7 point scale, 7 = delighted, 1= terrible</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" spread="1.3"/>
                    <measurement group_id="O2" value="3.94" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine</title>
          <description>Study drug, Duloxetine, 30 mg for 1 week, titrate up to 60 mg for 5 weeks and titrate back down to 30 mg for 1 week.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Matching placebo drug for 7 weeks total</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>headache</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="dizziness">dizziness</sub_title>
                <description>dizziness</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theodore R. Brown, MD Principle Investigator</name_or_title>
      <organization>MS Center at Evergreenhealth Care</organization>
      <phone>425-899-5350</phone>
      <email>trbrown@evergreenhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

